| Zacks Company Profile for Bio-Techne Corp (TECH : NSDQ) |
|
|
| |
| • Company Description |
| Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota.
Number of Employees: 3,100 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $61.10 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,805,930 shares |
| Shares Outstanding: 155.69 (millions) |
| Market Capitalization: $9,512.87 (millions) |
| Beta: 1.51 |
| 52 Week High: $80.80 |
| 52 Week Low: $46.01 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
3.23% |
2.36% |
| 12 Week |
15.65% |
10.09% |
| Year To Date |
-15.17% |
-26.32% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Kim Kelderman - President; Chief Executive Officer and Director
Robert V. Baumgartner - Chairman of the Board and Director
James Hippel - Chief Financial Officer
Julie Bushman - Director
Rupert Vessey - Director
|
|
Peer Information
Bio-Techne Corp (CORR.)
Bio-Techne Corp (RSPI)
Bio-Techne Corp (CGXP)
Bio-Techne Corp (BGEN)
Bio-Techne Corp (GTBP)
Bio-Techne Corp (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09073M104
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/05/25
|
|
Share - Related Items
Shares Outstanding: 155.69
Most Recent Split Date: 11.00 (4.00:1)
Beta: 1.51
Market Capitalization: $9,512.87 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.52% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.39 |
Indicated Annual Dividend: $0.32 |
| Current Fiscal Year EPS Consensus Estimate: $1.77 |
Payout Ratio: 0.18 |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: -0.02 |
| Estmated Long-Term EPS Growth Rate: 9.66% |
Last Dividend Paid: 08/18/2025 - $0.08 |
| Next EPS Report Date: 11/05/25 |
|
|
|
| |
